Cell & Gene: The Podcast

Erin Harris
undefined
Oct 14, 2021 • 25min

BridgeBio's Approach to Gene Therapy & Nearing the Clinic

We love to hear from our listeners. Send us a message.BridgeBio's CEO of Gene Therapy, Dr. Eric David, explains the company's gene therapy programs for Canavan disease and congenital adrenal hyperplasia, their manufacturing plans, and the platform underpinning their novel approach to gene therapy.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
undefined
Sep 30, 2021 • 20min

Inside Spark Therapeutics' Investigational SPK-8011 for Hemophilia A

We love to hear from our listeners. Send us a message.Spark Therapeutics' Clinical Development Lead, Hematology, Dr. Tiffany Chang explains the company's data from its ongoing Phase 1/2 clinical trial of investigational SPK-8011 for hemophilia A, the largest gene therapy trial in this disease to date as well as the misconceptions and unknowns about the disease.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
undefined
Sep 16, 2021 • 20min

Gene Therapies for Spinal Cord-Related Disorders with SwanBio's CEO

We love to hear from our listeners. Send us a message.Karen Kozarsky, Ph.D., Co-Founder and CSO of SwanBio, explains how the company is pioneering a deep and varied pipeline of gene therapies for genetically defined neurological diseases with a focus on the spinal cord.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
undefined
Sep 2, 2021 • 32min

Chronic Lymphocytic Leukemia: A Patient's Perspective

We love to hear from our listeners. Send us a message.Bob Levis was diagnosed with Chronic Lymphocytic Leukemia in 2002 and was one of the early experimental trial participants at Penn Medicine for Dr. Carl June’s CAR-T therapy. Bob shares his remarkable journey with CLL as well as his important work with the CLL Society.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
undefined
Aug 19, 2021 • 26min

State-of-the-Art GMP Manufacturing RNA Cell Therapies with Cartesian's CEO

We love to hear from our listeners. Send us a message.Dr. Murat Kalayoglu, CEO at Cartesian Therapeutics, details the cell and gene therapy sector’s advancements in RNA cell therapy and the why behind the company's decision to build its own wholly-owned GMP manufacturing facility.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
undefined
Aug 5, 2021 • 32min

Therapeutic Firsts and "Eds and Meds" with Penn’s Dr. Bruce Levine

We love to hear from our listeners. Send us a message.University of Pennsylvania’s Dr. Bruce Levine explains his road to adoptive immunotherapy trials, overcoming the gap between academia and industry, and how Philadelphia earned the "Cellicon Valley" name for its continued innovation in cell and gene therapy — and more.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
undefined
Jul 22, 2021 • 30min

Hospitals And Advanced Therapies with Penn Medicine’s Kevin Mahoney

We love to hear from our listeners. Send us a message.In this episode of Cell & Gene: The Podcast, University of Pennsylvania Health System’s CEO Kevin Mahoney talks to Host Erin Harris about how hospital systems must evolve to meet the needs of cell and gene therapy patients as these complex therapies are commercialized. They discuss what comprises UPHS and the ongoing innovation it brings to advanced therapies as well as how the Health System stays patient-focused at all costs.  Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
undefined
Jul 8, 2021 • 24min

Enzyvant's Rachelle Jacques on the Biotech’s Lead Asset

We love to hear from our listeners. Send us a message.During this first episode of Cell & Gene: The Podcast, Host Erin Harris talks to Enzyvant’s CEO Rachelle Jacques about the biotech’s lead asset, investigational regenerative therapy RVT-802 for congenital athymia. Jacques provides an update on FDA approval and details what’s next for RVT-802. She explains tissue-based therapies — how far they’ve come and the work that’s left to be done. And, they discuss what being patient-focused means in the world of rare diseases. Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn
undefined
Jun 30, 2021 • 2min

Introducing Cell & Gene: The Podcast

We love to hear from our listeners. Send us a message.Cell & Gene, the online resource that delivers in-depth content from authoritative authors and sources to professionals in the CGT sector, is thrilled to introduce “Cell & Gene: The Podcast.” Cell and gene therapies offer huge potential to treat a wide range of diseases and their possibilities represent a new era in medicine. “Cell & Gene: The Podcast” will explore approved and pipeline therapies, new trends in manufacturing, the long, regulated road to commercialization, and everything in between. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to an industry or academic leader about their current initiatives and how they are moving the sector forward.  (Music by Royalty Free Music From Bensound) Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app